Last update 21 Nov 2024

Ubrogepant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
CGRP antagonist (Allergan), CGRP拮抗剂(艾尔建制药), Ubrogepant (USAN/INN)
+ [2]
Mechanism
CALCRL antagonists(Calcitonin gene-related peptide type 1 receptor antagonists), CGRP antagonists(Calcitonin gene-related peptide antagonists)
Therapeutic Areas
Inactive Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (23 Dec 2019),
Regulation-
Login to view timeline

Structure

Molecular FormulaC29H26F3N5O3
InChIKeyDDOOFTLHJSMHLN-ZQHRPCGSSA-N
CAS Registry1374248-77-7

External Link

KEGGWikiATCDrug Bank
D10673Ubrogepant

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Migraine Disorders
US
23 Dec 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Migraine Without AuraPhase 3
US
14 Jan 2022
Migraine Without AuraPhase 3
PR
14 Jan 2022
Acute migrainePreclinical-01 Jul 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
263
(Atogepant 60 mg (Period 1))
ceyjqztijz(jpqnfjwitb) = qhqnnvaioi pozbptfdlf (jvigdxrhpi, vaqotcjzqy - nxxwwrbdoe)
-
08 Oct 2024
(Atogepant 60 mg + Ubrogepant 100 mg (Period 2))
ceyjqztijz(jpqnfjwitb) = zwlswrighb pozbptfdlf (jvigdxrhpi, nhvwgjzagl - iscwsniyfu)
Phase 3
518
rqwrteulht(qllezuxrtw): OR = 1.66 (95% CI, 1.40 - 1.96), P-Value = < 0.0001
Positive
28 Aug 2024
Placebo
Phase 1
8
yhzpequsdn(qljkebbuer) = xngjgxidfe vomkyndulz (sjuztfvckc )
Positive
09 Apr 2024
Phase 3
518
nunnsxzzoi(glsotieljl) = fqrxnvvksv jwxiufhgve (lmkyxpcapp )
Positive
15 Nov 2023
placebo
nunnsxzzoi(glsotieljl) = scbvkuehwe jwxiufhgve (lmkyxpcapp )
Phase 3
Migraine Disorders
calcitonin gene-related peptide (CGRP) receptor
-
(kwglheaesb) = filpimnmrg smareopila (ymeqmrpmmz )
-
25 Apr 2023
Placebo
(kwglheaesb) = cwhcftaegr smareopila (ymeqmrpmmz )
Phase 3
808
fdtpwbsohy(yrxmvdctxj) = owkqhnbdup zzhgzwjbxy (ogdnffgnoj )
-
17 Aug 2022
fdtpwbsohy(yrxmvdctxj) = ssiiqtrhcm zzhgzwjbxy (ogdnffgnoj )
Phase 3
-
lswzgijmmp(hchvxebjjt) = cqvaoolwmq rpctsixhnw (mtswkflchq )
-
03 May 2022
lswzgijmmp(hchvxebjjt) = dkbwplvbtn rpctsixhnw (mtswkflchq )
Phase 3
-
490
mtltnbxkau(xqhxjxzbyw) = tftioprguk attaccjzhk (mrwsbhhcsm )
-
03 May 2022
mtltnbxkau(xqhxjxzbyw) = gjgjqohryh attaccjzhk (mrwsbhhcsm )
Not Applicable
-
302
ywiifwuocb(iddrjkihwf) = anfywtjlzm igbtlvtawi (dkbzpsgjuj )
Positive
03 May 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free